» Articles » PMID: 33502600

Morphological Intratumor Heterogeneity in Ductal Carcinoma in Situ of the Breast

Overview
Journal Virchows Arch
Date 2021 Jan 27
PMID 33502600
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous disease in terms of morphological characteristics, protein expression profiles, genetic abnormalities, and potential for progression. Molecular heterogeneity has been extensively studied in DCIS. Yet morphological heterogeneity remains relatively undefined. This study investigated morphological intratumor heterogeneity in a series of 51 large DCIS. Nuclear atypia, DCIS architecture, necrosis, calcifications, stromal architecture, and stromal inflammation were assessed in one biopsy slide and three representative slides from each corresponding resection. For each histopathological feature, a histo-score was determined per slide and compared between the biopsy and the resection, as well as within a single resection. Statistical analysis comprised of Friedman tests, post hoc Wilcoxon tests with Bonferroni corrections, Mann-Whitney U tests, and chi-square tests. Despite substantial morphological heterogeneity in around 50% of DCIS, the histopathological assessment of the biopsy did not statistically significantly differ from the resection. Morphological heterogeneity was not significantly associated with patient age, DCIS size, or type of surgery, except for a weak association between heterogeneous stromal inflammation and smaller DCIS size. At the group level, the degree of heterogeneity did not significantly affect the representativity of a biopsy. At the individual patient level, however, the presence of necrosis, intraductal calcifications, myxoid stromal changes, and high-grade nuclear atypia was underestimated in a minority of DCIS patients. This study confirms the presence of morphological heterogeneity in DCIS for all six evaluated histopathological features. This should be kept in mind when taking biopsy-based treatment decisions for DCIS patients.

Citing Articles

The Predictive Role of Mammography, Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging and Diffusion-Weighted Imaging in Hormone Receptor Status of Pure Ductal Carcinoma Lesions.

Coskun Bilge A, Bulut Z Eur J Breast Health. 2024; 20(4):241-250.

PMID: 39323287 PMC: 11589184. DOI: 10.4274/ejbh.galenos.2024.2024-5-1.

References
1.
McCormick B, Winter K, Hudis C, Kuerer H, Rakovitch E, Smith B . RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015; 33(7):709-15. PMC: 4334775. DOI: 10.1200/JCO.2014.57.9029. View

2.
Ward E, DeSantis C, Lin C, Kramer J, Jemal A, Kohler B . Cancer statistics: Breast cancer in situ. CA Cancer J Clin. 2015; 65(6):481-95. DOI: 10.3322/caac.21321. View

3.
Chen X, Yeong J, Thike A, Bay B, Tan P . Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res Treat. 2019; 177(1):17-27. DOI: 10.1007/s10549-019-05272-2. View

4.
Van Bockstal M, Agahozo M, Koppert L, van Deurzen C . A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int J Cancer. 2019; 146(5):1189-1197. PMC: 7004157. DOI: 10.1002/ijc.32362. View

5.
Mardekian S, Bombonati A, Palazzo J . Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions. Hum Pathol. 2016; 49:114-23. DOI: 10.1016/j.humpath.2015.11.003. View